Bristol Myers Squibb (BMS) subsidiary Juno Therapeutics has lost a bid to persuade a U.S. appeals court to overturn its own decision tossing out a $1.2 billion patent verdict that Juno won against Gilead Sciences subsidiary Kite Pharma.
Source: Drug Industry Daily